STOCK TITAN

Augmedix, Inc. - $AUGX STOCK NEWS

Welcome to our dedicated page for Augmedix news (Ticker: $AUGX), a resource for investors and traders seeking the latest updates and insights on Augmedix stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Augmedix's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Augmedix's position in the market.

Rhea-AI Summary

Augmedix, Inc. (Nasdaq: AUGX) will participate in four investor conferences in May and June 2024, including RBC Capital Markets Global Healthcare Conference, Benchmark Healthcare House Call Conference, B. Riley Annual Institutional Investor Conference, and William Blair Annual Growth Stock Conference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.88%
Tags
conferences
-
Rhea-AI Summary

Augmedix (Nasdaq: AUGX) will announce its first quarter 2024 financial results on May 13, 2024. The company specializes in ambient AI medical documentation and data solutions. Management will host a conference call the same day at 1:30 p.m. PT / 4:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.24%
Tags
-
Rhea-AI Summary
Augmedix (Nasdaq: AUGX) has been recognized as one of the World's Best Digital Health Companies 2024 by Newsweek and Statista Inc. The award highlights Augmedix's commitment to empowering clinicians through ambient AI medical documentation solutions. Augmedix's platform converts natural conversations into structured medical notes, enhancing efficiency and clinical decision-making. The company's inclusion in the top 400 companies from over 35 countries is based on financial performance, impact, and online engagement criteria.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.15%
Tags
none
Rhea-AI Summary
Augmedix launches Augmedix Go, the industry’s first fully-automated, GenAI-powered medical documentation product for emergency departments. The product aims to improve patient experience, increase productivity, reduce cognitive burden, and shorten chart closure time. Augmedix Go was piloted with HCA Healthcare EDs, receiving positive feedback on note quality and AI accuracy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.35%
Tags
none
-
Rhea-AI Summary
Augmedix (AUGX) partners with Andor Health to enhance virtual care with ambient AI medical documentation, aiming to improve clinician-patient interactions and streamline workflows. The collaboration integrates AI-generated clinical notes within ThinkAndor® Virtual Visit, leveraging ambient documentation to transform care settings. Augmedix and Andor Health aim to optimize communication, reduce clinician burnout, and enhance patient outcomes through their innovative platforms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary
Augmedix (AUGX) partners with SADA, an Insight company, to accelerate digital health solutions and integrations. The collaboration aims to enhance ambient AI medical documentation and data products for health systems.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
Rhea-AI Summary
Augmedix (AUGX) reports impressive financial results for Q4 and full year 2023, showcasing revenue growth of 45% to $12.7 million and $44.9 million respectively. The company achieved a gross profit increase of 54% to $6.2 million and $21.5 million for the respective periods. Augmedix anticipates revenue of $60 to $62 million in 2024, reflecting strong growth prospects.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.92%
Tags
none
-
Rhea-AI Summary
Augmedix (AUGX) announces positive data and product enhancements for Augmedix Go, saving clinicians up to 1 hour per day in medical documentation. The app supports over 50 medical specialties, generating real-time draft notes from natural conversations. Survey data shows 94% of clinicians report better patient focus. Augmedix Go integrates with major EHRs and uses AI models for high-quality notes. CEO Manny Krakaris emphasizes the need for automated solutions to combat administrative burden and burnout.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5%
Tags
AI
-
Rhea-AI Summary
Augmedix (Nasdaq: AUGX) to Release Q4 and Full Year 2023 Results on March 18, 2024
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
Rhea-AI Summary
Augmedix, Inc. (Nasdaq: AUGX) will participate in the Citizens JMP Technology Conference in San Francisco on March 4, 2024. The management team will host a fireside chat and investor meetings, accessible through a webcast on the Company's IR website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.43%
Tags
conferences
Augmedix, Inc.

Nasdaq:AUGX

AUGX Rankings

AUGX Stock Data

133.19M
28.91M
10.17%
76.81%
1.71%
All Other Business Support Services
Administrative and Support and Waste Management and Remediation Services
Link
United States of America
SAN FRANCISCO

About AUGX

augmedix is a telemedicine charting service for healthcare providers that eliminates the 17 hours each week providers spend on ehr documentation. using wearable technology to connect their clinic with the augmedix charting service, providers can focus on what they do best: taking care of patients.